{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:57:35Z","timestamp":1794931055246,"version":"4.9.1"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Polypharmacology means drugs having interactions with multiple targets of a unique disease or many disease pathways. This concept has been greatly appreciated against complex diseases, such as oncology, CNS disorders, and anti-infectives.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The integration of diverse compounds available on public databases initiates polypharma-cological drug discovery research. Immunocompromised patients may suffer from complex diseas-es. Multiple-component drug formulations may produce side effects and resistance issues due to un-intended drug-target interactions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Polypharmacology remains a novel avenue to propose a more effective and less toxic treatment. The 4-amino quinoline scaffold has become an important construction motif for the de-velopment of new drugs against lifestyle diseases like cancer and infectious diseases like tuberculo-sis and malaria.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The present study is an attempt to explore the polypharmacological effects of 4-aminoquinoline drugs to combat malaria, cancer, and tuberculosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026623666230123142357","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:27:56Z","timestamp":1674476876000},"page":"403-414","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multi-target Polypharmacology of 4-aminoquinoline Compounds against\nMalaria, Tuberculosis and Cancer"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9960-6584","authenticated-orcid":true,"given":"Sisir","family":"Nandi","sequence":"first","affiliation":[{"name":"Global Institute of Pharmaceutical Education and Research, Kashipur, 244713, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-930X","authenticated-orcid":true,"given":"Bhumika","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Global Institute of Pharmaceutical Education and Research, Kashipur, 244713, India"},{"name":"Oxford College of Pharmacy,\nUPSIDC Industrial Area, Hapur, Uttar Pradesh, 201015, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-4270","authenticated-orcid":true,"given":"Heena","family":"Tarannum","sequence":"additional","affiliation":[{"name":"Global Institute of Pharmaceutical Education and Research, Kashipur, 244713, India"},{"name":"Pragati College of Pharmacy, Kashipur, 244713,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7149-2378","authenticated-orcid":true,"given":"Mayank Kumar","family":"Khede","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Institute of Pharmacy and Technology, Salipur, Affiliated to Biju Patnaik University\nof Technology, Odisha, 754202, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1586\/ecp.12.74","volume":"6","author":"Reddy A.S.","year":"2013","unstructured":"Reddy A.S.; Zhang S.; Polypharmacology: Drug discovery for the future. Expert Rev Clin Pharmacol 2013,6(1),41-47","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=2","first-page":"211","author":"Favre H.A.","year":"2014","unstructured":"Favre H.A.; Powell W.H.O.;  Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names 2013 2014,211","journal-title":"Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names 2013"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.molliq.2016.04.074","volume":"220","author":"Al-Ahmary K.M.","year":"2016","unstructured":"Al-Ahmary K.M.; Alenezi M.S.; Habeeb M.M.; Synthesis, spectroscopic and DFT theoretical studies on the hydrogen bonded charge transfer complex of 4-aminoquinoline with chloranilic acid. J Mol Liq 2016,220,166-182","journal-title":"J Mol Liq"},{"key":"ref=4","unstructured":"World Health OrganizationAvailable from:"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/3-540-29088-5_3","volume":"295","author":"Plowe C.V.","year":"2005","unstructured":"Plowe C.V.; Antimalarial drug resistance in Africa: Strategies for monitoring and deterrence. Curr Top Microbiol Immunol 2005,295,55-79","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0140-6736(01)05557-X","volume":"358","author":"Staedke S.G.","year":"2001","unstructured":"Staedke S.G.; Kamya M.R.; Dorsey G.; Gasasira A.; Ndeezi G.; Charlebois E.D.; Rosenthal P.J.; Amodiaquine, sulfadoxine\/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: A randomised trial. Lancet 2001,358(9279),368-374","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1128\/AAC.00100-12","volume":"56","author":"Pou S.","year":"2012","unstructured":"Pou S.; Winter R.W.; Nilsen A.; Kelly J.X.; Li Y.; Doggett J.S.; Riscoe E.W.; Wegmann K.W.; Hinrichs D.J.; Riscoe M.K.; Sontochin as a guide to the development of drugs against chloroquine-resistant malaria. Antimicrob Agents Chemother 2012,56(7),3475-3480","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jps.2600520621","volume":"52","author":"Nobles W.L.","year":"1963","unstructured":"Nobles W.L.; Tietz R.F.; Koh Y.S.; Burckhalter J.H.; Antimalarial Agents VIII. Synthesis of Amopyroquin J Pharm Sci 1963,52(6),600-601","journal-title":"Synthesis of Amopyroquin J Pharm Sci"},{"key":"ref=9","first-page":"650","volume":"34","author":"Rabinovich S.A.","year":"1965","unstructured":"Rabinovich S.A.; Experimental study of an antimalarial drug, haloquine (cycloquine). IV. Comparison of the prophylactic action of haloquine and chloroquine used in equal doses. Med Parazitol (Mosk) 1965,34(6),650-657","journal-title":"Med Parazitol (Mosk)"},{"key":"ref=10","first-page":"1","volume":"25","author":"Sharma S.","year":"1997","unstructured":"Sharma S.; Anand N.; Approaches to design and synthesis of antiparasitic drugs. Pharmacochem. Liberary 1997,25,1-511","journal-title":"Liberary"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1128\/AAC.00675-10","volume":"55","author":"Hocart S.J.","year":"2011","unstructured":"Hocart S.J.; Liu H.; Deng H.; De D.; Krogstad F.M.; Krogstad D.J.; 4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: Basis of antiparasite activity and quantitative structure-activity relationship analyses. Antimicrob Agents Chemother 2011,55(5),2233-2244","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s40064-015-1593-3","volume":"4","author":"Parihar N.","year":"2015","unstructured":"Parihar N.; Nandi S.; In silico combinatorial design and pharmacophore modeling of potent antimalarial 4-anilinoquinolines utilizing QSAR and computed descriptors. Springerplus 2015,4(1),819","journal-title":"Springerplus"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1021\/jm020858u","volume":"45","author":"Kaschula C.H.","year":"2002","unstructured":"Kaschula C.H.; Egan T.J.; Hunter R.; Basilico N.; Parapini S.; Taramelli D.; Pasini E.; Monti D.; Structure-activity relationships in 4-aminoquinoline antiplasmodials. The role of the group at the 7-position. J Med Chem 2002,45(16),3531-3539","journal-title":"J Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ijpddr.2017.10.005","volume":"7","author":"Chirawurah J.D.","year":"2017","unstructured":"Chirawurah J.D.; Ansah F.; Nyarko P.B.; Duodu S.; Aniweh Y.; Awandare G.A.; Antimalarial activity of malaria box compounds against Plasmodium falciparum clinical isolates. Int J Parasitol Drugs Drug Resist 2017,7(3),399-406","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"15896","DOI":"10.1038\/s41598-017-16154-2","volume":"7","author":"Kondratskyi A.","year":"2017","unstructured":"Kondratskyi A.; Kondratska K.; Vanden Abeele F.; Gordienko D.; Dubois C.; Toillon R.A.; Slomianny C.; Lemi&#xE8;re S.; Delcourt P.; Dewailly E.; Skryma R.; Biot C.; Prevarskaya N.; Ferroquine, the next generation antimalarial drug, has antitumor activity. Sci Rep 2017,7(1),15896","journal-title":"Sci Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(15)00079-1","volume":"15","author":"Held J.","year":"2015","unstructured":"Held J.; Supan C.; Salazar C.L.O.; Tinto H.; Bonkian L.N.; Nahum A.; Moulero B.; Si&#xE9; A.; Coulibaly B.; Sirima S.B.; Siribie M.; Otsyula N.; Otieno L.; Abdallah A.M.; Kimutai R.; Bouyou-Akotet M.; Kombila M.; Koiwai K.; Cantalloube C.; Din-Bell C.; Djeriou E.; Waitumbi J.; Mordm&#xFC;ller B.; TerMinassian D.; Lell B.; Kremsner P.G.; Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: A phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis 2015,15(12),1409-1419","journal-title":"Lancet Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1021\/jm960370r","volume":"40","author":"O\u2019Neill P.M.","year":"1997","unstructured":"O\u2019Neill P.M.; Willock D.J.; Hawley S.R.; Bray P.G.; Storr R.C.; Ward S.A.; Park B.K.; Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues. J Med Chem 1997,40(4),437-448","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1021\/jm030796n","volume":"46","author":"O\u2019Neill P.M.","year":"2003","unstructured":"O\u2019Neill P.M.; Mukhtar A.; Stocks P.A.; Randle L.E.; Hindley S.; Ward S.A.; Storr R.C.; Bickley J.F.; O\u2019Neil I.A.; Maggs J.L.; Hughes R.H.; Winstanley P.A.; Bray P.G.; Park B.K.; Isoquine and related amodiaquine analogues: A new generation of improved 4-aminoquinoline antimalarials. J Med Chem 2003,46(23),4933-4945","journal-title":"J Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e0140878","DOI":"10.1371\/journal.pone.0140878","volume":"10","author":"Rajapakse C.S.K.","year":"2015","unstructured":"Rajapakse C.S.K.; Lisai M.; Deregnaucourt C.; Sinou V.; Latour C.; Roy D.; Schr&#xE9;vel J.; S&#xE1;nchez-Delgado R.A.; Synthesis of new 4-aminoquinolines and evaluation of their in vitro activity against chloroquine-sensitive and chloroquine-resistant plasmodium falciparum. PLoS One 2015,10(10),e0140878","journal-title":"PLoS One"},{"key":"ref=20","year":"2022","unstructured":"Cancer World Health OrganizationAvailable from: 2022"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1038\/s41598-019-42816-4","volume":"9","author":"Solomon V.R.","year":"2019","unstructured":"Solomon V.R.; Pundir S.; Lee H.; Examination of novel 4-aminoquinoline derivatives designed and synthesized by a hybrid pharmacophore approach to enhance their anticancer activities. Sci Rep 2019,9(1),6315","journal-title":"Sci Rep"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/aps.2014.3","volume":"35","author":"Liu F.","year":"2014","unstructured":"Liu F.; Shang Y.; Chen S.; Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro. Acta Pharmacol Sin 2014,35(5),645-652","journal-title":"Acta Pharmacol Sin"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.colsurfb.2012.02.039","volume":"95","author":"Joshi P.","year":"2012","unstructured":"Joshi P.; Chakraborti S.; Ramirez-Vick J.E.; Ansari Z.A.; Shanker V.; Chakrabarti P.; Singh S.P.; The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells. Colloids Surf B Biointerfaces 2012,95,195-200","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1021\/ic802220w","volume":"48","author":"Rajapakse C.S.K.","year":"2009","unstructured":"Rajapakse C.S.K.; Mart&#xED;nez A.; Naoulou B.; Jarzecki A.A.; Su&#xE1;rez L.; Deregnaucourt C.; Sinou V.; Schr&#xE9;vel J.; Musi E.; Ambrosini G.; Schwartz G.K.; S&#xE1;nchez-Delgado R.A.; Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine. Inorg Chem 2009,48(3),1122-1131","journal-title":"Inorg Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1021\/ml3000808","volume":"3","author":"Manohar S.","year":"2012","unstructured":"Manohar S.; Rajesh U.C.; Khan S.I.; Tekwani B.L.; Rawat D.S.; Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity. ACS Med Chem Lett 2012,3(7),555-559","journal-title":"ACS Med Chem Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jhet.3791","author":"Bhat H.R.","year":"2019","unstructured":"Bhat H.R.; Masih A.; Shakya A.; Ghosh S.K.; Singh U.P.; Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4\u2010aminoquinoline\u20101, 3, 5\u2010triazine derivatives. J Heterocycl Chem 2019,1-10","journal-title":"J Heterocycl Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1039\/C4NJ00936C","volume":"39","author":"Kandi S.K.","year":"2015","unstructured":"Kandi S.K.; Manohar S.; V&#xE9;lez Gerena C.E.; Zayas B.; Malhotra S.V.; Rawat D.S.C.; 5 -curcuminoid-4-aminoquinoline based molecular hybrids: Design, synthesis and mechanistic investigation of anticancer activity. New J Chem 2015,39(1),224-234","journal-title":"New J Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2478\/acph-2014-0030","volume":"64","author":"Ghorab M.M.","year":"2014","unstructured":"Ghorab M.M.; Al-Said M.S.; Arafa R.K.; Design, synthesis and potential anti-proliferative activity of some novel 4-aminoquinoline derivatives. Acta Pharm 2014,64(3),285-297","journal-title":"Acta Pharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3797\/scipharm.0905-07","volume":"77","author":"Ferrer R.","year":"2009","unstructured":"Ferrer R.; Lobo G.; Gamboa N.; Rodrigues J.; Synthesis of [(7-Chloroquinolin-4-yl)amino]chalcones: Potential antimalarial and anticancer agents. Sci Pharm 2009,77,725","journal-title":"Sci Pharm"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5870","DOI":"10.3390\/molecules17055870","volume":"17","author":"Jiang N.","year":"2012","unstructured":"Jiang N.; Zhai X.; Li T.; Liu D.; Zhang T.; Wang B.; Gong P.; Design, synthesis and antiproliferative activity of novel 2-substituted-4-amino-6-halogenquinolines. Molecules 2012,17(5),5870-5881","journal-title":"Molecules"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3892\/ijo.2019.4824","volume":"55","author":"Wang W.","year":"2019","unstructured":"Wang W.; Liu L.; Zhou Y.; Ye Q.; Yang X.; Jiang J.; Ye Z.; Gao F.; Tan X.; Zhang G.; Fang Q.; Xuan Z.X.; Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer. Int J Oncol 2019,55(2),405-414","journal-title":"Int J Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3332\/ecancer.2017.781","volume":"11","author":"Verbaanderd C.","year":"2017","unstructured":"Verbaanderd C.; Maes H.; Schaaf M.B.; Sukhatme V.P.; Pantziarka P.; Sukhatme V.; Agostinis P.; Bouche G.; Repurposing Drugs in Oncology (ReDO)\u2014chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience 2017,11,781","journal-title":"Ecancermedicalscience"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4314\/tjpr.v19i2.1","volume":"19","author":"Elshazly E.H.","year":"2020","unstructured":"Elshazly E.H.; Zhang S.; Yu L.; Zhang Y.; Ke L.; Gong R.; Hydroxychloroquine enhances anticancer effect of DOX\/folate-phytosterol-carboxymethyl cellulose nanoparticles in A549 lung cancer cells. Trop J Pharm Res 2020,19(2),219-225","journal-title":"Trop J Pharm Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.36108\/pajols\/1202.50.0240","volume":"5","author":"Salako K.S.","year":"2021","unstructured":"Salako K.S.; Chukwuemeka P.A.; Moshood O.A.; Boladale O.S.; Screening of amodiaquine for its in vitro anti-cancer activity on breast cancer cell lines- a case study for drug reprofiling. PAJOLS 2021,5(2),263-273","journal-title":"PAJOLS"},{"key":"ref=35","author":"T.B.C. India","unstructured":"T.B.C. India;  Guidelines for Programmatic Management of Tuberculosis Preventive Treatment in India Available from:","journal-title":"Guidelines for Programmatic Management of Tuberculosis Preventive Treatment in India"},{"key":"ref=36","author":"T.B.C. India","year":"2022","unstructured":"T.B.C. India;  India annual TB Report Available from: 2022","journal-title":"India annual TB Report"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/1062936X.2017.1419375","volume":"29","author":"Nandi S.","year":"2018","unstructured":"Nandi S.; Ahmed S.; Saxena A.K.; Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling. SAR QSAR Environ Res 2018,29(2),151-170","journal-title":"SAR QSAR Environ Res"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/B978-1-4160-3988-4.00006-8","author":"Grange J.M.","year":"2009","unstructured":"Grange J.M.;  Tuberculosis: A comprehensive clinical reference 2009,44-59","journal-title":"Tuberculosis: A comprehensive clinical reference"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.282.7.677","volume":"282","author":"Dye C.","year":"1999","unstructured":"Dye C.; Scheele S.; Dolin P.; Pathania V.; Raviglione M.C.; Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999,282(7),677-686","journal-title":"JAMA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/13543776.2022.2012151","volume":"32","author":"Ahmed S.","year":"2022","unstructured":"Ahmed S.; Nandi S.; Saxena A.K.; An updated patent review on drugs for the treatment of tuberculosis (2018-present). Expert Opin Ther Pat 2022,32(3),243-260","journal-title":"Expert Opin Ther Pat"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.2174\/1568026620666200903163921","volume":"20","author":"Dey R.","year":"2020","unstructured":"Dey R.; Nandi S.; Samadder A.; Saxena A.; Saxena A.K.; Exploring the potential inhibition of candidate drug molecules for clinical investigation based on their docking or crystallographic analyses against M. tuberculosis enzyme targets. Curr Top Med Chem 2020,20(29),2662-2680","journal-title":"Curr Top Med Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3998\/ark.5550190.0007.a25","volume":"2006","author":"Mital A.","year":"2006","unstructured":"Mital A.; Negi V.S.; Ramachandran U.; Synthesis and antimycobacterial activities of certain trifluoromethyl-aminoquinoline derivatives. ARKIVOC 2006,2006(10),220-227","journal-title":"ARKIVOC"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s43094-019-0016-7","volume":"6","author":"Alegaon S.","year":"2020","unstructured":"Alegaon S.; Kashniyal K.; Kuncolienkar S.; Kavalapure R.; Salve P.; Palled M.; Suryawanshi S.; Jalalpure S.; Synthesis and biological evaluation of some 4-aminoquinoline derivatives as potential antitubercular agents. Future J Pharm Sci 2020,6(1),2","journal-title":"Future J Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"127576","DOI":"10.1016\/j.bmcl.2020.127576","volume":"30","author":"Rani A.","year":"2020","unstructured":"Rani A.; Johansen M.D.; Roquet-Ban&#xE8;res F.; Kremer L.; Awolade P.; Ebenezer O.; Singh P.; Sumanjit; Kumar, V. Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials. Bioorg Med Chem Lett 2020,30(22),127576","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.4155\/fmc-2017-0098","volume":"9","author":"Singh A.","year":"2017","unstructured":"Singh A.; Viljoen A.; Kremer L.; Kumar V.; Azide-alkyne cycloaddition en route to 4-aminoquinoline-ferrocenylchalcone conjugates: synthesis and anti-TB evaluation. Future Med Chem 2017,9(15),1701-1708","journal-title":"Future Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"10782","DOI":"10.1002\/slct.201702220","volume":"2","author":"Rani A.","year":"2017","unstructured":"Rani A.; Viljoen A.; Sumanjit; Kremer, L.; Kumar, V. Microwave-assisted highly efficient route to 4-aminoquinoline-phthalimide conjugates: Synthesis and anti-tubercular evaluation. ChemistrySelect 2017,2(33),10782-10785","journal-title":"ChemistrySelect"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bmcl.2017.02.031","volume":"27","author":"Salve P.S.","year":"2017","unstructured":"Salve P.S.; Alegaon S.G.; Sriram D.; Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors. Bioorg Med Chem Lett 2017,27(8),1859-1866","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.bmcl.2009.12.045","volume":"20","author":"Eswaran S.","year":"2010","unstructured":"Eswaran S.; Adhikari A.V.; Pal N.K.; Chowdhury I.H.; Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. Bioorg Med Chem Lett 2010,20(3),1040-1044","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.biopha.2011.01.003","volume":"65","author":"Carmo A.M.L.","year":"2011","unstructured":"Carmo A.M.L.; Silva F.M.C.; Machado P.A.; Fontes A.P.S.; Pavan F.R.; Leite C.Q.F.; Leite S.R.A.; Coimbra E.S.; Da Silva A.D.; Synthesis of 4-aminoquinoline analogues and their platinum (II) complexes as new antileishmanial and antitubercular agents. Biomed Pharmacother 2011,65(3),204-209","journal-title":"Biomed Pharmacother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"114908","DOI":"10.1016\/j.ejmech.2022.114908","volume":"245","author":"Paz J.D.","year":"2023","unstructured":"Paz J.D.; Denise de Moura Sperotto N.; Ramos A.S.; Pissinate K.; da Silva Rodrigues Junior, V.; Abbadi B.L.; Borsoi A.F.; Rambo R.S.; Corso Minotto A.C.; da Silva Dadda A.; Galina L.; Macchi Hopf F.S.; Muniz M.N.; Borges Martinelli L.K.; Roth C.D.; Madeira Silva R.B.; Perell&#xF3; M.A.; de Matos Czeczot A.; Neves C.E.; Duarte L.S.; Leyser M.; Dias de Oliveira S.; Bizarro C.V.; Machado P.; Basso L.A.; Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation. Eur J Med Chem 2023,245(Pt 1),114908","journal-title":"Eur J Med Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2015.06.032","volume":"103","author":"Medapi B.","year":"2015","unstructured":"Medapi B.; Suryadevara P.; Renuka J.; Sridevi J.P.; Yogeeswari P.; Sriram D.; 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation. Eur J Med Chem 2015,103,1-16","journal-title":"Eur J Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1021\/ml300134b","volume":"3","author":"Shirude P.S.","year":"2012","unstructured":"Shirude P.S.; Paul B.; Roy Choudhury N.; Kedari C.; Bandodkar B.; Ugarkar B.G.; Quinolinyl pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents. ACS Med Chem Lett 2012,3(9),736-740","journal-title":"ACS Med Chem Lett"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"Diacon A.H.","year":"2009","unstructured":"Diacon A.H.; Pym A.; Grobusch M.; Patientia R.; Rustomjee R.; Page-Shipp L.; Pistorius C.; Krause R.; Bogoshi M.; Churchyard G.; Venter A.; Allen J.; Palomino J.C.; De Marez T.; van Heeswijk R.P.G.; Lounis N.; Meyvisch P.; Verbeeck J.; Parys W.; de Beule K.; Andries K.; Neeley D.F.M.; The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009,360(23),2397-2405","journal-title":"N Engl J Med"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230123142357","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213029\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230123142357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:14:16Z","timestamp":1683112456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213029\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026623666230123142357","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}